Profile data is unavailable for this security.
About the company
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
- Revenue in USD (TTM)0.00
- Net income in USD-7.07m
- Incorporated2023
- Employees9.00
- LocationTNF Pharmaceuticals Inc855 N. Wolfe Street, Suite 601BALTIMORE 21205United StatesUSA
- Websitehttps://tnfpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qrons Inc | 0.00 | -860.04k | 2.59m | 2.00 | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.088 | 0.00 | -- | -- | 0.00 | -9,368.63 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -9.21 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| GB Sciences Inc | 0.00 | -1.64m | 2.65m | 2.00 | -- | -- | -- | -- | -0.0041 | -0.0041 | 0.00 | -0.0131 | 0.00 | -- | -- | 0.00 | -597.54 | -31.80 | -- | -297.29 | -- | -- | -- | -- | -- | -6.49 | -- | -- | -- | -- | 60.24 | -- | -- | -- |
| TNF Pharmaceuticals Inc | 0.00 | -7.07m | 2.96m | 9.00 | -- | 0.1275 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -8.68m | 3.03m | 8.00 | -- | 0.476 | -- | -- | -23.77 | -23.77 | 0.00 | 7.40 | 0.00 | -- | -- | 0.00 | -98.62 | -71.92 | -126.86 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Allarity Therapeutics Inc | 0.00 | -12.82m | 3.12m | 5.00 | -- | 0.1301 | -- | -- | -2,217.58 | -2,217.58 | 0.00 | 16.98 | 0.00 | -- | -- | 0.00 | -52.54 | -- | -110.73 | -- | -- | -- | -- | -- | -- | -- | 0.0626 | -- | -- | -- | 3.02 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -15.90m | 3.17m | 9.00 | -- | 1.22 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 3.22m | 0.00 | -- | 1.73 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -8.88m | 3.26m | 2.00 | -- | 0.4646 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.32m | 5.00 | -- | 1.85 | -- | 6.55 | -0.6188 | -0.6188 | 0.074 | 0.224 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Talis Biomedical Corp | 408.00k | -51.03m | 3.37m | 99.00 | -- | 0.0693 | -- | 8.26 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.38m | 21.00 | -- | 0.4050 | -- | 0.8195 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Trevena Inc | 443.00k | -37.03m | 3.42m | 23.00 | -- | -- | -- | 7.72 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.42m | 5.00 | -- | 0.4687 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 30 Jun 2024 | 15.82k | 0.67% |
| Geode Capital Management LLCas of 30 Jun 2024 | 14.41k | 0.61% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 13.69k | 0.58% |
| Virtu Americas LLCas of 30 Jun 2024 | 11.69k | 0.49% |
| Iroquois Capital Management LLCas of 24 May 2024 | 6.72k | 0.28% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.80k | 0.16% |
| Parallel Advisors LLCas of 30 Jun 2024 | 838.00 | 0.04% |
| Group One Trading LPas of 30 Jun 2024 | 387.00 | 0.02% |
| Vanguard Global Advisers LLCas of 30 Jun 2024 | 310.00 | 0.01% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 266.00 | 0.01% |
